- Home
- CING vs VYNE Comparison
CING vs VYNE Comparison
Compare CING & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CING
- VYNE
- Stock Information
- Founded
- CING 2012
- VYNE 2003
- Country
- CING United States
- VYNE United States
- Employees
- CING N/A
- VYNE N/A
- Industry
- CING Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- CING Health Care
- VYNE Health Care
- Exchange
- CING Nasdaq
- VYNE Nasdaq
- Market Cap
- CING 16.2M
- VYNE 16.0M
- IPO Year
- CING 2021
- VYNE 2018
- Fundamental
- Price
- CING $4.25
- VYNE $1.43
- Analyst Decision
- CING Strong Buy
- VYNE Strong Buy
- Analyst Count
- CING 4
- VYNE 2
- Target Price
- CING $30.67
- VYNE $6.25
- AVG Volume (30 Days)
- CING 104.9K
- VYNE 1.3M
- Earning Date
- CING 08-12-2025
- VYNE 08-13-2025
- Dividend Yield
- CING N/A
- VYNE N/A
- EPS Growth
- CING N/A
- VYNE N/A
- EPS
- CING N/A
- VYNE N/A
- Revenue
- CING N/A
- VYNE $605,000.00
- Revenue This Year
- CING N/A
- VYNE $42.51
- Revenue Next Year
- CING N/A
- VYNE N/A
- P/E Ratio
- CING N/A
- VYNE N/A
- Revenue Growth
- CING N/A
- VYNE 43.03
- 52 Week Low
- CING $1.80
- VYNE $0.85
- 52 Week High
- CING $20.83
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- CING 59.00
- VYNE 56.77
- Support Level
- CING $3.97
- VYNE $0.85
- Resistance Level
- CING $4.26
- VYNE $1.96
- Average True Range (ATR)
- CING 0.27
- VYNE 0.20
- MACD
- CING 0.00
- VYNE 0.07
- Stochastic Oscillator
- CING 74.56
- VYNE 51.80
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.